Assets (2 total) 2 Total Assets
0 Approved
0 Phase 3 / Filed
2 Phase 1–2 / Early
4 Diseases
Disease: All diseases (2) Non-Small Cell Lung Cancer (2) Cervical Cancer (1) Head and Neck Squamous Cell Carcinoma (1) Esophageal Cancer (1)
Stage: All stages (2) Approved / Phase 4 (0) Phase 3 / Filed (0) Phase 2 Phase 1 / Preclinical
Quick filter: All (2) Non-Small Cell Lung Cancer (2) Cervical Cancer (1) Head and Neck Squamous Cell Carcinoma (1) Esophageal Cancer (1)
Showing 2 of 2 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 1/2 Claudin-1 (CLDN1) Antibody–drug conjugate
Non-Small Cell Lung Cancer Cervical Cancer Head and Neck Squamous Cell Carcinoma Esophageal Cancer
Esophageal Squamous Cell Carcinoma Phase 1/2 Claudin-1 (CLDN1) Antibody–drug conjugate
Non-Small Cell Lung Cancer
Upcoming events (2 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2028 (1) February 2028 (1) ALE.P02 Phase 1/2 Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma … Est. primary completion 2028-02-15 ·
NCT06747585 ·
CT.gov ↗ What to watch
2029 (1) April 2029 (1) ALE.P03 Phase 1/2 Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma … Est. primary completion 2029-04-05 ·
NCT07169734 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Financial reports No financial reports recorded.